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ABSTRACT
Background We measured N-terminal pro-brain
natriuretic peptide (NT-pro-BNP), a marker of cardiac
dysfunction, in an inception cohort with early
inflammatory polyarthritis (IP) and assessed its
association with disease phenotype, cardiovascular
disease (CVD), all-cause and CVD related mortality.
Methods Subjects with early IP were recruited to the
Norfolk Arthritis Register from January 2000 to
December 2008 and followed up to death or until
March 2010 including any data from the national death
register. The associations of baseline NT-pro-BNP with IP
related factors and CVD were assessed by linear
regression. Cox proportional hazards models examined
the independent association of baseline NT-pro-BNP
with all-cause and CVD mortality.
Results We studied 960 early IP subjects; 163 (17%)
had prior CVD. 373 (39%) patients had a baseline NT-
pro-BNP levels ≥100 pg/ml. NT-pro-BNP was associated
with age, female gender, HAQ score, CRP, current
smoking, history of hypertension, prior CVD and the
presence of carotid plaque. 92 (10%) IP subjects died
including 31 (3%) from CVD. In an age and gender
adjusted analysis, having a raised NT-pro-BNP level
(≥100 pg/ml) was associated with both all-cause and
CVD mortality (adjusted HR (95% CI) 2.36 (1.42 to
3.94) and 3.40 (1.28 to 9.03), respectively). These
findings were robust to adjustment for conventional CVD
risk factors and prevalent CVD.
Conclusions In early IP patients, elevated NT-pro-BNP
is related to HAQ and CRP and predicts all-cause and
CVD mortality independently of conventional CVD risk
factors. Further study is required to identify whether
NT-pro-BNP may be clinically useful in targeting intensive
interventions to IP patients at greatest risk of CVD.
BACKGROUND
N-terminal pro-brain-type natriuretic peptide
(NT-pro-BNP) is an inactive and stable amino acid
fragment cosecreted, alongside the neuroendocrine
peptide BNP, from the ventricular cardiac myocytes.
It is released in response to left ventricular strain or
ischaemia and has been found to be an important
biomarker for left ventricular systolic dysfunction
and left ventricular stress in the general popula-
tion.1 Levels are also elevated even in those
without clinical cardiovascular disease (CVD) and
even minimally elevated NT-pro-BNP levels are
predictive of future CVD and mortality in a range
of cohort and general healthy population
studies.2–5 These observations have also been con-
firmed in a meta-analysis of 40 studies involving
87 474 subjects and 10 625 incident CVD out-
comes.6 In clinical practice, an NT-pro-BNP level
of ≥100 pg/ml has high sensitivity and specificity
for congestive heart failure (CHF) and can be used
to stratify patients at high risk of cardiac failure in
the acute setting.7–9 Circulating NT-pro-BNP is also
associated with pro-inflammatory cytokines such as
tumour necrosis factor (TNF) and interleukin 6
(IL-6).10 Acute inflammatory conditions including
pneumonia and septic shock are also associated
with raised NT-pro-BNP levels11–17 and TNF
blockade in rheumatoid arthritis (RA) lowers
NT-pro-BNP, suggesting a link between inflamma-
tion and cardiac stress. This has raised interest in
the role of NT-pro-BNP in chronic inflammatory
conditions such as inflammatory polyarthritis (IP).
IP and RA are associated with an excess CVD
risk including coronary heart disease, stroke and
CHF.18–21 In two recent meta-analyses, the standar-
dised mortality ratio (95% CI) for coronary heart
disease and stroke in RAwas 1.50 (1.39 to 1.61)22 and
1.46 (1.31 to 1.63),23 respectively. CHF has also been
noted to be a common cause of death inRA and chronic
inflammationmay contribute to this outcome.24
A small number of studies have examined the
potential relevance of NT-pro-BNP levels in RA
patients. Crowson et al25 noted higher NT-pro-BNP
levels in RA compared with population controls. In
established RA, NT-pro-BNP was associated with
disease activity, disease duration as well as with C
reactive protein (CRP), TNF and IL-6 concentra-
tions.26–29 One study from our group found that a
reduction in NT-pro-BNP correlated with the reduc-
tion in erythrocyte sedimentation rate observed
after starting adalimumab therapy.30 A further study
also noted an association between NT-pro-BNP and
carotid intima-medial thickness (cIMT).28 To date,
only one study has looked at the predictive value of
NT-pro-BNP levels with future CVD mortality in
established RA;29 however, little is known about
NT-pro-BNP in early IP patients.
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The aim of this study was to measure serum NT-pro-BNP
levels in a large, well characterised inception cohort of patients
with early IP. First, we aimed to examine the baseline association
of NT-pro-BNP levels with IP disease phenotype, clinical CVD
risk markers and subclinical atherosclerosis surrogates. Second,
we also examined the predictive value of raised NT-pro-BNP
levels for future all-cause and CVD related mortality.
METHODS
Setting
Subjects aged 16 years and older with early IP (≥2 joints
swollen for ≥4 weeks) were recruited to the Norfolk Arthritis
Register (NOAR) from January 2000 to December 2008. In this
study, we restricted inclusion to subjects with ≤24 months’
symptom duration.
Data collection at recruitment
All subjects underwent a clinical assessment including swollen
and tender joint count (51 joints), measurement of height and
weight to calculate body mass index (BMI). Smoking status was
recorded and patients were categorised into never smokers, pre-
vious smokers or current smokers. Subjects were specifically
asked about past history of CVD events such as angina, heart
attacks and heart failure, as well as current prescribed and
over-the-counter medications and any history of disease modify-
ing antirheumatic drugs use. All patients completed the Health
Assessment Questionnaire (HAQ). Hypertension was defined as
being present if patients reported a physician diagnosis of hyper-
tension or if they were taking antihypertensive therapy at the
baseline clinical assessment. Diabetes mellitus was also defined
by patient self-report of a physician diagnosis or if they were
taking oral hypoglycaemic agents or injected insulin.
Blood sample analysis
At recruitment blood samples were collected, aliquoted and
frozen at −80°C in Norfolk before being transported to the
Arthritis Research UK Epidemiology Unit in Manchester. A
Nephrostar Galaxy automated analyser was used to determine
CRP concentration (BMG Labtech, Aylesbury, UK); this was
used to calculate the 28-joint disease activity score (DAS28CRP).
Rheumatoid factor (RF) was measured using a particle enhanced
immunoturbidimetric assay where >40 iU/ml was considered
positive for RF (BMG Labtech). Antibodies to citrullinated
protein antigens (ACPA) were measured using the Axis-Shield
DIASTAT kit (Axis-Shield, Dundee, UK) where >5 U/ml was
considered positive for ACPA. Patients were considered ‘sero-
positive’ if they had a positive RF and/or ACPA.
Serum NT-pro-BNP concentrations were determined using the
Elecsys 2010 electrochemiluminescence method (Roche
Diagnostics, Burgess Hill, UK), calibrated using the manufacturer’s
reagents at the University of Glasgow (PW, NS). Manufacturer’s
controls were used with limits of acceptability defined by the
manufacturer. The limit of detection was 5 pg/ml. Low control
coefficient of variance (CV) was 6.7% and high control CV was
4.9%. Patients were classified as having a raised NT-pro-BNP level
if their NT-pro-BNP measurement was ≥100 pg/ml as per local
clinically used threshold and published data.7–9
Cardiovascular substudy
In a subset of the main cohort, consecutive patients (n=327)
recruited between 2004 and 2008 and aged 18–65 years at
cohort entry were invited to participate in a detailed cardio-
vascular assessment. A fasting blood sample was used to
measure the lipid profile and plasma glucose. Blood pressure
was measured in each arm and the higher of the two measure-
ments was used in analyses. For the purposes of this study,
however, hypertension was defined in all cases as described
above. They also underwent a B-mode Doppler carotid ultra-
sound examination at the Department of Vascular Radiology
at the Norfolk and Norwich University Hospital. The images
were stored on super video home system (VHS) video and
analysed at The University of Manchester, Department of
Vascular Surgery using a standardised research protocol.
Preliminary validation has revealed good intraobserver correl-
ation using this technique.31 Briefly, the right and left
common carotid artery, carotid bulb and the first 1.5 cm of
the internal and external carotid arteries were examined in
longitudinal and cross-sectional planes. Carotid IMT measure-
ments were made in a longitudinal plane at a point of
maximum thickness on the far wall of the common carotid
artery along a 1 cm section of the artery proximal to the
carotid bulb. Measurements were repeated three times on
each side, unfreezing the image on each occasion and relocat-
ing the maximal cIMT. The average of these three measure-
ments was then calculated and used as the mean cIMT.32 The
higher of the right or left mean cIMT was used as the cIMT
for analyses. Carotid plaque was defined as present if any of
the following parameters was met and then graded according
to standard definitions:33
1. plaque present with <30% vessel diameter loss
2. 30%–50% vessel diameter loss
3. >50% vessel diameter loss.
Total cholesterol, high density lipoprotein (HDL) and trigly-
cerides were assayed on fresh fasting serum using cholesterol
oxidase phenol aminopjenazone (CHOD-PAP), a homogen-
ous direct method (Abbott Diagnostics, Berkshire, UK), and
glycerol-3-phosphate oxidaze (GPO-PAP) methods respectively
at the Norfolk and Norwich University Hospital. Low density
lipoprotein (LDL) levels were mathematically derived using the
Friedwald’s equation.
Follow-up and mortality
In NOAR all patients are flagged with the National Health
Service Information Service (NHS-IS). Patients were followed up
until March 2010, death or embarkation, whichever came first.
Death certificates were provided by the NHS-IS for all those who
had died. For this study we took the underlying cause of death,
coded using ICD10,34 as the main cause of death. CV deaths
were defined as those where the underlying cause of death fell
within chapter I of ICD10. All patients provided written
informed consent to take part and the study was approved by the
Norfolk Research Ethics Committee (REC no. 2003/075).
Statistical analyses
As the NT-pro-BNP levels were positively skewed, we log-
transformed these values for our analysis. The associations
among log-transformed NT-pro-BNP and baseline demographic,
IP and CVD parameters including the presence or absence of
carotid plaque at recruitment were assessed using linear regres-
sion. These analyses were subsequently adjusted for age at
recruitment and gender. Forward stepwise multivariable regres-
sion analysis was carried out that included age and gender to
assess key IP and CVD related factors associated with log
NT-pro-BNP levels at baseline on univariate analyses (p<0.05).
We examined the association of raised NT-pro-BNP
(≥100 pg/ml) with mortality (all-cause and CVD) using Cox
proportional hazards regression. Analyses were adjusted for key
CVD risk factors, namely, age, gender, BMI, prior CVD,
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diabetes, smoking status and hypertension. Subsequently ana-
lyses were adjusted for IP related factors associated with log
NT-pro-BNP in our cross-sectional analysis. Incremental prog-
nostic information was calculated using the Harrell’s C-statistic
(C-index) and these values were compared using the χ2 test.
Sensitivity analyses were also undertaken in the subsets who (i)
were negative for ACPA and RF and (ii) had no reported history
of prior CVD at baseline recruitment.
RESULTS
Cross-sectional association of baseline NT-pro-BNP
concentration with IP disease phenotype and CVD risk
markers
We studied 960 IP subjects with a median (IQR) age and
symptom duration of 58 (47–68) years and 5.9 (3.2–10.5)
months, respectively. The cohort included 617 (64%) female
subjects; there were 211 (25%) current smokers. In all, 484/823
(59%) were positive for RF and/or ACPA and 436 (45%) ful-
filled the 1987 American College for Rheumatology Criteria for
RA at first assessment (table 1). A history of prior CVD was
reported by 163 (17%) patients (table 1). The demographic, IP
phenotype and CVD parameters were comparable in the subset
of 327 patients who had carotid Doppler scans relative to the
entire cohort, with the exception of a younger median age at
recruitment into this substudy as per protocol (table 1).
NT-pro-BNP levels were positively skewed with a median
(IQR) of 74 (38–153) pg/ml; 373 (39%) patients had
NT-pro-BNP levels ≥100 pg/ml, including 89 of 163 (55%)
patients with a prior history of CVD. In univariate linear regres-
sion analyses, higher log NT-pro-BNP levels were associated
Table 1 Baseline characteristics of the IP cohort and the CVD substudy population
Variables
Number of subjects with
data in total population
Total study population
Median (IQR)/mean (SD)/n(%)
n=960
Number of subjects with
data in CVD substudy
CVD substudy population
Median (IQR)/mean (SD)/n(%)
n=327
Demographics
Age (years) 960 58 (47–68) 327 51 (42–58)*
Female 960 617 (64%) 327 232 (71%)
IP disease parameters
RF/ACPA positive 823 484 (59%) 322 162 (50%)
RA, 1987 ACR criteria 960 436 (45%) 327 152 (46%)
HAQ score 946 0.88 (0.38–1.50) 325 0.88 (0.38–1.38)
DAS28CRP 842 3.7 (2.8–4.6) 305 3.8 (3.0–4.8)
Swollen joints (/28) 960 2 (0–6) 327 3 (1–6)
Tender joints (/28) 960 3 (0–8) 327 4 (1–10)
CRP (mg/l) 842 11 (5–22) 305 11 (8–20)
Symptom duration (months) 960 5.9 (3.2–10.5) 327 6.5 (4.2–11.2)
Treatments
DMARDs 960 496 (52%) 327 182 (56%)
Steroids 960 245 (26%) 327 60 (18%)
NSAIDs 960 344 (36%) 327 212 (65%)
COX-2 inhibitor 960 83 (9%) 327 15 (5%)
Paracetamol 960 164 (17%) 327 129 (39%)
Antihypertensive therapy 960 193 (20%) 327 42 (13%)
Statin therapy 960 17 (2%) 327 24 (7%)
CVD parameters
BMI (kg/m2) 940 26.4 (23.6–30.1) 320 26.7 (24.1–31.0)
Diabetes 960 88 (9%) 327 31 (9%)
Current smoker 845 211/845 (25%) 269 74 (28%)
Previous smoker 845 378/845 (45%) 269 127 (47%)
Never smoker 845 256/845 (30%) 269 68 (25%)
Prior CVD 960 163 (17%) 327 14 (4%)
Hypertensive 960 208 (22%) 327 44 (13%)
BP (mm Hg) NA – 327 134/83 (17/10)
Systolic BP (mm Hg) NA – 327 133 (17)
Diastolic BP (mm Hg) NA – 327 83 (10)
Total cholesterol (mmol/l) NA – 327 5.3 (4.7–6.0)
LDL (mmol/l) NA – 327 3.3 (2.7–3.9)
HDL (mmol/l) NA – 327 1.4 (1.1–1.7)
Fasting glucose (mg/dl) NA – 327 4.8 (4.5–5.1)
CVD surrogates
cIMT (mm) NA – 327 0.06 (0.05–0.07)
Carotid plaque NA – 327 150 (46%)
*Statistically significantly different at p<0.05.
ACPA, anticitrulinated protein antibody; ACR, American College for Rheumatology; BMI, body mass index; BP, blood pressure; cIMT, carotid intima-medial thickness; COX-2,
cyclo-oxygenase-2 inhibitor; CRP, C reactive protein; CVD, cardiovascular disease; DAS28, disease activity score based on 28 joint count; DMARD, disease modifying antirheumatic drug;
HAQ, Health Assessment Questionnaire; IP, inflammatory polyarthritis; mm Hg, millimetres of mercury; NA, data not available; NSAID, non-steroidal anti-inflammatory drug; RA,
rheumatoid arthritis; RF, rheumatoid factor.
686 Mirjafari H, et al. Ann Rheum Dis 2014;73:684–690. doi:10.1136/annrheumdis-2012-202848
Clinical and epidemiological research
 group.bmj.com on April 2, 2014 - Published by ard.bmj.comDownloaded from 
with being older at recruitment (β-coefficient (95% CI) 0.035
(0.031 to 0.039) per year) and female (β-coefficient (95% CI)
0.211 (0.085 to 0.336)). In univariate age and gender adjusted
analyses (table 1), a number of factors were associated with log
NT-pro-BNP including prior CVD, classic risk factors such as
previous smoking and hypertension and several IP related
factors, including HAQ score, and CRP. Both BMI and tender
joint counts were negatively associated with log NT-pro-BNP
(table 2).
In a multivariable forward stepwise linear regression analysis
containing all risk markers showing significance on univariate
analyses, age, prior CVD and hypertension all remained posi-
tively associated and BMI remained negatively associated with
log NT-pro-BNP (table 2). IP related factors that remained asso-
ciated on multivariable analysis were HAQ score (β-coefficient
(95% CI) 0.250 (0.149 to 0.351)), CRP (β-coefficient (95% CI)
0.002 (0.001 to 0.004)) and tender joint count (β-coefficient
(95% CI) −0.021 (−0.032 to −0.010)).
Cross-sectional association of baseline NT-pro-BNP
concentration with subclinical atherosclerosis
The presence of plaque was significantly associated with log
NT-pro-BNP levels (β-coefficient (95% CI) 0.253 (0.063 to
0.442)). This association did not however persist after age and
gender adjustment (β-coefficient (95% CI) 0.109 (−0.100 to
0.319)). Carotid IMT was not significantly associated with
NT-pro-BNP levels on univariate analysis.
NT-pro-BNP levels and mortality
During 5526 patient years of follow-up over a median (IQR)
follow-up period of 5.5 (3.7–7.7) years, 92 (10%) IP subjects
died. Of the 92 deaths, 31 (34%) had the main underlying
cause of death as CVD (Chapter I of ICD10), 31 (34%) died
due to neoplastic conditions (Chapter II of ICD10), 15 (16%)
due to respiratory disease (Chapter X of ICD10) and the
remaining 15 (16%) had other causes of death cited.
The overall and CVD related mortality rates were 16.8 (95%
CI 16.7 to 16.9) and 5.8 per 1000 patient years (95% CI 5.6 to
5.9), respectively. Of the subjects with a baseline NT-pro-BNP
level <100 pg/ml, 25 (4%) died during the follow-up period.
This accounted for 27% of all deaths. In subjects with
NT-pro-BNP ≥100 pg/ml, 67 (18%) died which accounted for
73% of all deaths in the cohort.
In a Cox proportional hazards model adjusted for age and
gender (table 3, model A), NT-pro-BNP ≥100 pg/ml was asso-
ciated with all-cause (HR (95% CI) 2.36 (1.42 to 3.94)) and
CVD mortality (HR (95% CI) 3.40 (1.28 to 9.03)). These asso-
ciations remained when we adjusted for additional CVD risk
factors (model B) or additional IP related factors (model C)
(table 3). Our final adjusted model (model D) also demonstrated
an independent association between NT-pro-BNP and all-cause
mortality (HR (95% CI) 2.15 (1.19 to 3.88)). The association
between NT-pro-BNP and CVD mortality was no longer signifi-
cant in the model (model D) that included both CVD and IP
related factors (HR (95% CI) 2.18 (0.76 to 6.27)) (table 3).
We examined the additional prognostic value of NT-pro-BNP
on mortality. The model predicting overall mortality using only
age and gender had a C-index of 0.787 which increased to
0.796 with the addition of standard CVD risk parameters; this
increase was not significant (model A vs B p=0.15). The add-
ition of NT-pro-BNP to standard CVD risk factors increased the
C-index to 0.812 which was a statistically significant increase
from the model including CVD risk factors (model B vs B plus
NT-pro-BNP p=0.0014). The model predicting CVD mortality
using only age and gender had a C-index of 0.817 which
increased to 0.831 with the addition of standard CVD risk
Table 2 Cross-sectional association between log NT-pro-BNP and demographic and disease related factors measured at baseline n=960
Variable
Log NT-pro-BNP*
β-Coefficient (95% CI)
Adj A&G†
Log NT-pro-BNP*
β-Coefficient (95% CI)
Stepwise regression‡
Age (per year) 0.035 (0.031 to 0.039) 0.025 (0.020 to 0.030)
Female (Y/N) 0.211 (0.085 to 0.336) –
ACR 1987 criteria (Y/N) 0.061 (−0.060 to 0.182)
RF/ACPA (Y/N) 0.009 (−0.111 to 0.129)
HAQ score (per unit) 0.119 (0.036 to 0.201) 0.250 (0.149 to 0.351)
DAS28CRP (per unit) −0.024 (−0.089 to 0.041)
Swollen joints (/28) (per joint) 0.008 (−0.005 to 0.020)
Tender joints (/28) (per joint) −0.009 (−0.018 to −0.0004) −0.021 (−0.032 to −0.010)
CRP (per mg/l) 0.003 (0.001 to 0.004) 0.002 (0.001 to 0.004)
Symptom duration (per month) −0.009 (−0.020 to 0.002)
DMARDs/steroids (Y/N) 0.045 (−0.079 to 0.169)
Duration of DMARD/steroid therapy (per month) 0.002 (−0.004 to 0.008)
Hypertension 0.282 (0.128 to 0.436) 0.196 (0.017 to 0.375)
BMI (per kg/m2) −0.020 (−0.031 to −0.008) −0.019 (−0.032 to −0.006)
Diabetes (Y/N) 0.011 (−0.020 to 0.222)
Current smoker (vs never smokers) 0.087 (−0.068 to 0.241)
Previous smoker (vs never smokers) 0.198 (0.021 to 0.376) –
Prior CVD (Y/N) 0.175 (0.014 to 0.337) 0.245 (0.059 to 0.431)
Statin therapy (Y/N) 0.022 (−0.462 to 0.507)
*Log NT-pro-BNP, NT-pro-BNP levels that have been log transformed.
†Linear regression models adjusted for age and gender.
‡Stepwise regression includes age, gender, HAQ score, tender joint count, CRP, hypertension, BMI, smoking status and prior CVD in the entire cohort.
ACPA, antibodies to citrullinated protein antigens; ACR, American College for Rheumatology; BMI, body mass index; CRP, C reactive protein; CVD, cardiovascular disease; DAS28,
disease activity score based on 28 joint count; DMARD, disease modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; NA, not applicable; NT-pro-BNP, N-terminal
pro-brain natriuretic peptide; RF, rheumatoid factor.
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parameters; this increase was not significant (model A vs B
p=0.17). The addition of NT-pro-BNP to model B of standard
CVD risk factors increased the C-index to 0.848 which was a
statistically significant increase from the model including CVD
risk factors alone (model B vs B plus NT-pro-BNP p=0.04).
Additional sensitivity analyses
The association of raised NT-pro-BNP with all-cause mortality
remained in an analysis restricted to patients who were sero-
negative for RF and ACPA (n=339) (HR (95% CI) 6.36 (3.01
to 13.44), fully adjusted HR (95% CI) 2.94 (1.04 to 8.23)) and
in those patients with no prior CVD (n=721) (HR (95% CI)
3.97 (2.38 to 6.62), fully adjusted HR (95% CI) 1.93 (1.00 to
3.72)), respectively. In these smaller subsets, the association with
CVD mortality was not statistically significant (data on file).
DISCUSSION
In a large inception cohort of patients with early IP we found
that NT-pro-BNP was associated with both a prior history of
CVD and also with higher CRP and HAQ scores. More import-
antly, NT-pro-BNP was independently associated with all-cause
and CVD mortality even after adjustment for conventional CVD
risk factors. As far as we are aware this is the first study to
address these questions in early IP and therefore our results are
of importance in further examining the value of NT-pro-BNP
measurement in stratifying IP patients for future mortality risk
from the outset of their disease.
A number of previous studies have shown that NT-pro-BNP
concentrations are elevated in RA compared with population con-
trols.26 27 Some of these have also noted an association between
inflammation and NT-pro-BNP levels.25–27 Inflammation has been
proposed as an important contributor to the pathogenesis of
cardiac dysfunction in RA patients. Maradit-Kremers et al24
showed that in a study of 575 patients with RA, episodes of heart
failure were often temporally associated with elevations in erythro-
cyte sedimentation rate. They hypothesised that inflammation dir-
ectly compromised left ventricular function, akin to the model of
myocardial depression and dysfunction seen in acute sepsis.35 Our
data support this paradigm as raised NT-pro-BNP has previously
been associated with IL-6 levels in other studies26 and in our popu-
lation was independently associated with higher CRP. The associ-
ation with HAQ scores was also significant in our multivariate
analysis. In early IP, HAQ scores tend to be closely associated with
inflammatory disease activity.36 Disability and functional status
may also be associated with a more sedentary lifestyle and may
also in part reflect unmeasured ‘frailty’ or other comorbidities
which may add to the association between HAQ and NT-pro-BNP
that we observed.
No prior studies have reported on the association of
NT-pro-BNP and BMI in early arthritis. We found log
NT-pro-BNP levels to be associated with lower BMI in early IP
which accords with the results of Wang et al who found that in
the Framingham cohort individuals with a high BMI had low
NT-pro-BNP levels.37 This association is broadly in agreement
with recent data showing that genetic predisposition to slightly
elevated circulating NT-pro-BNP is protective of diabetes.38 In
the patients who had a more detailed cardiovascular assessment,
we found that log NT-pro-BNP was not significantly associated
with atherosclerotic plaque or carotid IMT after age and gender
adjustment. This is also in agreement with data in patients with
diabetes.39 This may be partially because carotid IMT is a rela-
tively weak surrogate of CVD risk, although plaque presence
may be a more credible marker of vascular risk.40 41 Recent evi-
dence indicates that NT-pro-BNP predicts risk of CVD even in
middle-aged men without minor ECG abnormalities and thus
the association of NT-pro-BNP with CVD appears to extend
beyond abnormalities in cardiac function and atherosclerosis.42
From a prognostic viewpoint, our raw data demonstrated a
much higher mortality rate among patients with elevated
NT-pro-BNP at baseline; indeed, 73% of all deaths over a
median follow-up of 5.5 (3.7–7.7) years were in this subset.
Following adjustment for age, sex and IP related covariates or
CVD related covariates this association was attenuated but
remained statistically significant. The lack of association with
CVD mortality after full adjustment may reflect the smaller
numbers in this subgroup relative to the number of dependent
variables we adjusted for. Overall our study had 69% power to
detect a doubling of overall mortality and 19% power to detect
a doubling of CVD mortality. Nevertheless, our observations
have prognostic relevance as NT-pro-BNP assessment in early IP
may identify patients with a particularly high risk of future mor-
tality and in particular cardiovascular death. Our study extends
and confirms the previous study by Provan et al29 who studied
182 patients from the EURIDISS cohort with 5–9-year disease
duration. In this cohort, NT-pro-BNP was independently asso-
ciated with all-cause mortality over a 10-year follow-up period.
Previous work has noted that the anti-TNF agent adalimumab is
associated with a reduction in NT-pro-BNP concentrations and
may also improve pulse pressure in RA.30 It will be interesting
to determine whether there will be added value in using either
Table 3 Raised NT-pro-BNP (≥100 pg/ml) level associations with increased all-cause and cardiovascular mortality in early inflammatory
polyarthritis
Model
All-cause mortality
HR (95% CI)
CVD mortality
HR (95% CI)
Unadjusted 4.58 (2.89 to 7.25) 7.09 (2.91 to 17.30)
A
Age and gender adjusted 2.36 (1.42 to 3.94) 3.40 (1.28 to 9.03)
B
Age, gender, hypertension, BMI, diabetes, smoking status, prior CVD 2.32 (1.36 to 3.96) 2.71 (1.00 to 7.37)
C
Age, gender, RF and/or ACPA positive, HAQ score, tender joint count, CRP 2.22 (1.28 to 3.86) 2.76 (1.00 to 7.63)
D
Fully adjusted model* 2.15 (1.19 to 3.88) 2.18 (0.76 to 6.27)
*Fully adjusted model included age at recruitment, gender, hypertension, BMI, diabetes, smoking status, prior CVD, RF and/or ACPA status, HAQ score, tender joint count and CRP.
ACPA, antibodies to citrullinated protein antigens; BMI, body mass index; CRP, C reactive protein; CVD, cardiovascular disease; HAQ, Health Assessment Questionnaire; NT-pro-BNP,
N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor.
688 Mirjafari H, et al. Ann Rheum Dis 2014;73:684–690. doi:10.1136/annrheumdis-2012-202848
Clinical and epidemiological research
 group.bmj.com on April 2, 2014 - Published by ard.bmj.comDownloaded from 
anti-TNF drugs or IL-6 blockade in this particular subset of
early RA patients not only to improve inflammation but
improve cardiac dysfunction.
This study has a number of strengths. It is a prospective study
of a large well described inception cohort with comprehensive
data on mortality. The clinical and laboratory data collections
were standardised and well established. There are some limita-
tions that are also worth considering. A limitation of the study
is that we do not have available to us a large control group of
healthy individuals drawn from the same population who have
prospective data in which to examine the influence of
NT-pro-BNP on future mortality. Despite this, the findings in
our early IP cohort can be compared with that in similar studies
in the general population. In agreement with our study popula-
tion studies have shown that NT-pro-BNP is associated with
worse CVD outcomes. A previous study from a Dutch popula-
tion found that 16.6% of individuals had raised NT-pro-BNP
compared with 39% in our study. As expected the mortality in
the general population was lower than in our study.4 The
NT-pro-BNP levels were measured on serum samples collected
at baseline recruitment into NOAR. We have only included sub-
jects with ≤24 months of symptom duration but nevertheless it
is possible that subjects had subclinical inflammatory disease for
a longer, albeit unspecified, period of time prior to being
recruited. It is also possible that some patients will have received
anti-inflammatory treatments which may have altered their
NT-pro-BNP levels, although raised NT-pro-BNP levels were
not associated with the duration of symptoms or disease modi-
fying antirheumatic drug and/or steroid use. Another potential
limitation of the study was that certain comorbid conditions
which may influence NT-pro-BNP levels were not included and
adjusted for in our analysis. The major variables that are known
to affect NT-pro-BNP levels such as age, gender, diabetes, prior
CVD, hypertension, smoking status and BMI were however
included. Echocardiographic and electrocardiographic data were
not available for this study; therefore, it is uncertain whether
the increase in NT-pro-BNP is solely due to increased cardiac
strain. Raised NT-pro-BNP levels are also associated with other
variables contributing to mortality in patients with IP which we
have not measured such as anaemia of chronic disease, renal
impairment, impaired glucose tolerance and concomitant infec-
tion as found in patients affected with HIV.43 Studies are also
needed to investigate why these patients have apparently
increased cardiac stress. Advanced atherosclerosis, both that
which is clinically evident and subclinical cardiac disease, is
arguably the principal contributor to the left ventricular strain.
Crowson et al25 noted that echocardiographic evidence of left
ventricular diastolic dysfunction was not as strongly associated
with raised NT-pro-BNP in RA than in population controls.
Therefore, while the prognostic value of NT-pro-BNP in RA is
clear from our study, further work is necessary to dissect the
precise mechanisms by which this association is mediated.
Certainly, our data suggest NT-pro-BNP may also capture some
aspects of a chronic inflammatory state and in this way pick up
vascular risk from both conventional and RA related risk
pathways.
In conclusion, our results suggest NT-pro-BNP may have utility
as part of a screening strategy to identify IP patients who may
benefit from a more aggressive risk management programme for
CVD. In particular, better understanding of the relationship
between NT-pro-BNP and cardiac/vascular outcomes in patients
with inflammatory disease may help achieve more targeted anti-
inflammatory and cardioprotective approaches in this high risk
population.
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